TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32569494

Group type: EXPERIMENTAL
Intervention: Ocular examination (external and slit) in ICU and COVID wards
Number of subjects: 142

Group type: COMPARATOR
Intervention: Patients with ocular manifestations
Number of subjects: 142

Group type: COMPARATOR
Intervention: Patients admitted to ICU
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Conjunctival hyperemia
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Chemosis
Number of subjects: 142
Study: 35771607

Group type: EXPERIMENTAL
Intervention: Full intervention arm (exercise intervention with Fitbit One)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Light intervention arm (minimal exercise intervention with Fitbit One)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Full intervention arm
Number of subjects: 75

Group type: COMPARATOR
Intervention: Light intervention arm
Number of subjects: 75
Study: 34344019

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 24
Study: 36209209

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with glucose meter, blood test-strips, log-book, waste management box, and training on SMBG in addition to usual care.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (routine monthly medical consultation and health education)
Number of subjects: 80
Study: 33129680

Group type: EXPERIMENTAL
Intervention: Investigational stocking (27–29 mmHg pressure at the medial supramalleolar level, no compression in foot and heel)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard stocking (23–32 mmHg)
Number of subjects: 47
Study: 33213125

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 120 mg HA, 240 mg CS, and 300 mg K once a day for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (arthrocentesis only)
Number of subjects: 30
Study: 35345251

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study: 33476387

Group type: EXPERIMENTAL
Intervention: remdesivir
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 33783257

Group type: EXPERIMENTAL
Intervention: Trauma‐Focused Cognitive Behavioral Therapy (TF‐CBT)
Number of subjects: 99
Study: 34210340

Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate (BGF) 320/18/9.6 μg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glycopyrrolate/formoterol fumarate (GFF) 18/9.6 μg
Number of subjects: 23
Study: 35431231

Group type: EXPERIMENTAL
Intervention: Geriatric EC
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Nongeriatric EC
Number of subjects: 342
Study: 32729789

Group type: COMPARATOR
Intervention: Inulin (control)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PROMITOR® Soluble Corn Fiber 70 (SCF70)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PROMITOR® Soluble Corn Fiber 85B (SCF85B)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: SCF70 and SCF85B
Number of subjects: 19
Study: 36121651

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy (360 mg Q3W or 240 mg Q2W plus XELOX or FOLFOX)
Number of subjects: 208
Study: 33523728

Group type: EXPERIMENTAL
Intervention: CTO percutaneous coronary intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic Total Occlusion Academic Research Consortium
Number of subjects: 0
Study: 35553827

Group type: EXPERIMENTAL
Intervention: EX+MitoQ (20 mg/day, oral)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: EX+MitoQ
Number of subjects: 32

Group type: COMPARATOR
Intervention: EX
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MitoQ
Number of subjects: 32
Study: 33269951

Group type: EXPERIMENTAL
Intervention: erenumab 70 mg
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: erenumab 140 mg
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: erenumab (64 weeks treatment)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: erenumab (delayed reversion)
Number of subjects: 358
Study: 33966283

Group type: EXPERIMENTAL
Intervention: BACtrack Mobile Pro
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BACtrack Vio
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohoot
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Floome
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Drinkmate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Evoc
Number of subjects: 20

Group type: COMPARATOR
Intervention: Police-grade device (Intoxilyzer 240)
Number of subjects: 20
Study: 34426994

Group type: EXPERIMENTAL
Intervention: Rethink My Drink (internet-delivered intervention)
Number of subjects: 842

Group type: COMPARATOR
Intervention: Alcohol: The Facts (online patient information booklet)
Number of subjects: 842
Study: 32798723

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (10 mL) added to 1000 mL saline solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline alone (1000 mL)
Number of subjects: 100
Study: 35232299

Group type: EXPERIMENTAL
Intervention: Online sexual and urinary rehabilitation curriculum tailored for this population
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Online recruitment strategies
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Online sex/dating application
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Cancer support site
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Social networking site
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Clinic-based recruitment
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Online recruitment methods
Number of subjects: 401
Study: 32913166

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) applied post-surgery for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group without KT application
Number of subjects: 60
Study: 35915267

Group type: EXPERIMENTAL
Intervention: NARC-15 tablets oxycodone-acetaminophen 5/325 mg (A-OXY)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: NSAID-15 tablets ibuprofen (IBU) 600 mg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CNSL-15 tablets A-OXY, 15 tablets IBU, and preoperative counseling
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study: 33524440

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) intervention with a self-selected daily 10-hour window between 6 AM and 8 PM
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) intervention
Number of subjects: 17
Study: 32221736

Group type: EXPERIMENTAL
Intervention: Post-ERAS® group
Number of subjects: 487

Group type: COMPARATOR
Intervention: Pre-ERAS® group
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Outpatient subgroup
Number of subjects: 487

Group type: COMPARATOR
Intervention: Inpatient subgroup
Number of subjects: 487
Study: 36360738

Group type: EXPERIMENTAL
Intervention: Guided ACT-based online intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual
Number of subjects: 89
Study: 35467312

Group type: EXPERIMENTAL
Intervention: Evolocumab + Statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ezetimibe + Statins
Number of subjects: 0
Study: 33255787

Group type: EXPERIMENTAL
Intervention: (6S)‐5‐Methyl‐THF‐Na salt (Arcofolin®)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: (6S)‐5‐Methyl‐THF‐Na and (6S)‐5‐Methyl‐THF‐Ca
Number of subjects: 24
Study: 32142563

Group type: EXPERIMENTAL
Intervention: Leukocyte- and platelet-rich fibrin membranes from smokers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Leukocyte- and platelet-rich fibrin membranes from nonsmokers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Advanced platelet-rich fibrin membranes from smokers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Advanced platelet-rich fibrin membranes from nonsmokers
Number of subjects: 60
Study: 36135341

Group type: EXPERIMENTAL
Intervention: Goal-Directed Hemodynamic Therapy (GDHT)
Number of subjects: 70
Study: 33477821

Group type: EXPERIMENTAL
Intervention: Alive A. muciniphila
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pasteurized A. muciniphila
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32065533

Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modelled placebo
Number of subjects: 0
Study: 34534172

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.5 ng/ml; n=40)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Propofol (1.7 μg/ml; n=40)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.9% end-tidal; n=39)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: S-ketamine (0.75 μg/ml; n=20)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 160
Study: 32800319

Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PCI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 120
Study: 33790002

Group type: EXPERIMENTAL
Intervention: sensor-Based Electronic Monitoring for Asthma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33757688

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (BTX-A) injection into masticatory muscles (masseter and temporalis) 2 weeks prior to surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline injection into masticatory muscles (masseter and temporalis) 2 weeks prior to surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (BTX-A) injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 20
Study: 36093647

Group type: EXPERIMENTAL
Intervention: 100 mg/L CS‐OL‐NPs
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5% glutaraldehyde solution (GA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1 mg/ml chitosan (CS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Deionized Water (DW)
Number of subjects: 20
Study: 33956212

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both HIIT and MICT
Number of subjects: 20
Study: 32965052

Group type: EXPERIMENTAL
Intervention: CAD-CAM milled bar with long distal extensions (MBDE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Retentive anchors (RA)
Number of subjects: 40
Study: 35162197

Group type: EXPERIMENTAL
Intervention: UP150 intervention (EG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual office environment (CG)
Number of subjects: 45
Study: 34405565

Group type: COMPARATOR
Intervention: Tadalafil alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tadalafil plus SC BNP
Number of subjects: 20
Study: 32915027

Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Support Group (SG)
Number of subjects: 95
Study: 36006877

Group type: EXPERIMENTAL
Intervention: Spirituality as a coping mechanism
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mental duress due to heavy workloads and fear of infection
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Negative social perception of HCPs
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Urban-rural disparities in access to medical supplies and peer support
Number of subjects: 5
Study: 33051045

Group type: EXPERIMENTAL
Intervention: Anthocyanin supplementation (125 mg, three times a day)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 35227790

Group type: EXPERIMENTAL
Intervention: Conventional 3-dimensional conformal radiation therapy (CR)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Hypofractionated tomotherapy (TT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both CR and TT
Number of subjects: 84
Study: 33203471

Group type: EXPERIMENTAL
Intervention: eMBI (mindmom application)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 280
Study: 35383680

Group type: EXPERIMENTAL
Intervention: RPE (ratings of perceived exertion) of 3-4 on the 10-point modified Borg scale
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 60-80% of heart rate reserve (HRR) with heart rate monitored by telemetry
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 60-80% of HRR with a personal HR monitor (HRM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 48
Study: 33792555

Group type: EXPERIMENTAL
Intervention: App-based transitional care (study group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Routine telephone follow-up (control group)
Number of subjects: 98
Study: 32354952

Group type: EXPERIMENTAL
Intervention: 24% oral sucrose solution (0.8 ml/kg)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Enteral feed alone
Number of subjects: 425
Study: 36073213

Group type: EXPERIMENTAL
Intervention: Nomogram based on systemic inflammation markers and conventional risk factors
Number of subjects: 430
Study: 34216034

Group type: EXPERIMENTAL
Intervention: tDCS targeting L-DLPFC and SM1 simultaneously
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: tDCS targeting L-DLPFC alone
Number of subjects: 57

Group type: COMPARATOR
Intervention: tDCS targeting SM1 alone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 57
Study: 32213044

Group type: EXPERIMENTAL
Intervention: INT (10 s work: 5 s recovery)
Number of subjects: 14

Group type: COMPARATOR
Intervention: HICT (12‐30 min, maximal effort, constant load cycle bouts)
Number of subjects: 14
Study: 34538500

Group type: EXPERIMENTAL
Intervention: Laryngeal tube insertion attempt
Number of subjects: 2146

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation attempt
Number of subjects: 2146
Study: 32210268

Group type: EXPERIMENTAL
Intervention: Scrambled body stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal layout stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin conductance response
Number of subjects: 0
Study: 34921834

Group type: EXPERIMENTAL
Intervention: Messages describing economic consequences of ACEs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Messages describing racial equity consequences of ACEs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups receiving messages about ACE prevalence or resilience
Number of subjects: 0
Study: 34659415

Group type: EXPERIMENTAL
Intervention: Abdominal massage with Salvia officinalis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (abdominal massage with Salvia officinalis, abdominal massage, control)
Number of subjects: 60
Study: 36014763

Group type: EXPERIMENTAL
Intervention: Glucose (1 g/kg BM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fructose (1 g/kg BM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose and Fructose (0.5 g/kg BM each)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sucralose (0.2 g in 300 mL)
Number of subjects: 12
Study: 33563372

Group type: EXPERIMENTAL
Intervention: Expiratory Flow Accelerator (EFA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 50
Study: 32274576

Group type: EXPERIMENTAL
Intervention: Combined physiotherapy and coaching intervention (5 individual coaching sessions plus opening and closing session)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 65
Study: 34360494

Group type: EXPERIMENTAL
Intervention: Self-reported physical fitness (overall fitness, cardiorespiratory fitness, muscular strength, flexibility)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Greater speed-agility
Number of subjects: 117

Group type: COMPARATOR
Intervention: Oxytocin administration to induce or stimulate labour
Number of subjects: 117
Study: 32932304

Group type: EXPERIMENTAL
Intervention: Medicaid patients
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Private patients
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: Private patients triaged by clinician
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: Medicaid patients triaged by clinician
Number of subjects: 1245
Study: 35579605

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 226
Study: 33674243

Group type: EXPERIMENTAL
Intervention: Oxygen breathing
Number of subjects: 34

Group type: COMPARATOR
Intervention: Room air breathing
Number of subjects: 34
Study: 32442136

Group type: EXPERIMENTAL
Intervention: Use of smartphones and tablets
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Use of specific apps or software to support memory
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Use of smartphones and tablets among caregivers
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Use of specific apps or software to support memory among caregivers
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Technophilia in people with dementia/mild cognitive impairment vs caregivers
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Technology enthusiasm
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Technology anxiety
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Technophilia associations in people with dementia/mild cognitive impairment
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Technophilia associations in caregivers
Number of subjects: 1086
Study: 35789257

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every four weeks
Number of subjects: 206
Study: 32805405

Group type: EXPERIMENTAL
Intervention: Cannabinoid use
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Cannabinoid study
Number of subjects: 151
Study: 35182213

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral TAPB with 40 ml of 0.375% ropivacaine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group received 40 ml of 0.9% normal saline
Number of subjects: 58
Study: 32980853

Group type: EXPERIMENTAL
Intervention: Midwife-managed clinic service providing diet and exercise education before week 16
Number of subjects: 592

Group type: COMPARATOR
Intervention: Routine antenatal care (control group)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Midwife-managed clinic service (No-IVF subgroup)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Midwife-managed clinic service (overweight group)
Number of subjects: 592
Study: 33259430

Group type: EXPERIMENTAL
Intervention: Ultracongruent TKA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Posterior-stabilized TKA
Number of subjects: 50
Study: 33150497

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg twice daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted)
Number of subjects: 72
Study: 32960954

Group type: EXPERIMENTAL
Intervention: Index guidance
Number of subjects: 214

Group type: COMPARATOR
Intervention: Unguided management
Number of subjects: 214
Study: 36057884

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 600 mg daily for 8 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 32962536

Group type: EXPERIMENTAL
Intervention: Twinkle artifact (TA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (without TA)
Number of subjects: 0
Study: 32664962

Group type: EXPERIMENTAL
Intervention: Simvastatin (lipophilic)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Pravastatin (hydrophilic)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 35239898

Group type: EXPERIMENTAL
Intervention: Xpert® MTB/RIF assay (Xpert)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Line probe assay (LPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MGITTM 960 (control)
Number of subjects: 0
Study: 33221252

Group type: EXPERIMENTAL
Intervention: 5-minute mindfulness session
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control track
Number of subjects: 53
Study: 32627646

Group type: EXPERIMENTAL
Intervention: Self-persuasion intervention
Number of subjects: 241

Group type: COMPARATOR
Intervention: Social norms control condition
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control condition focusing on sense of belongingness
Number of subjects: 241
Study: 36143215

Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment (PST) for 8 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment (PST)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 61
Study: 32046311

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 7 × 2 min cycling repetitions, 3 days/week for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continuous moderate-intensity training - 20-30 min cycling, 3 days/week for 8 weeks
Number of subjects: 24
Study: 35361163

Group type: EXPERIMENTAL
Intervention: ROSE group
Number of subjects: 198

Group type: COMPARATOR
Intervention: Non-ROSE group (Control)
Number of subjects: 198
Study: 34008842

Group type: EXPERIMENTAL
Intervention: 900 µg vitamin D3
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 900 µg 25(OH)D3
Number of subjects: 16
Study: 32603774

Group type: EXPERIMENTAL
Intervention: Single-Isocenter SRS
Number of subjects: 73

Group type: COMPARATOR
Intervention: Multiple-Isocenter SRS
Number of subjects: 73
Study: 36233716

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Midazolam (MDZ)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: High risk for OSA
Number of subjects: 115
Study: 34605079

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 660

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660